Pharmaceuticals

NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year

SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program  (CT Program), delivered by Aust...

2022-11-04 11:35 2439

ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the initial results from a global Phase II st...

2022-11-04 03:33 2350

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from three studies of ...

2022-11-04 03:32 1799

Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters

NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters. After nearly four years of court proceedings, the Honorable Valerie E. Caproni ofthe United States District Court for the Southern District o...

2022-11-04 01:37 2646

Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022

Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRN...

2022-11-03 21:30 2243

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...

2022-11-03 21:10 1815

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and ...

2022-11-03 21:01 2034

Yuyu Pharma attendance at European Pharmaceutical Conference

SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma, has been attending biopharmaceutical conferences held inGermany, BIO-Europe and CPHI. The purpose is to explore opportunities to expand into international markets, such as Europe. 

2022-11-03 21:00 1650

Zhongchao Inc.'s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market

SHANGHAI, Nov. 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of theChina operating entities of which the Company cons...

2022-11-03 19:30 1545

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...

2022-11-03 19:00 1436

Malaysia Seeks Strategic Global Partnerships to Accelerate Its Growth Trajectory As A Preferred Healthcare Destination

Explore the potentials of Malaysia Healthcare at World Travel Market London 2022 LONDON, Nov. 3, 2022 /PRNewswire/ -- Malaysia Healthcare is strengthening its global proposition for preventive healthcare via strategic partnerships at the World Travel Market 2022 ("WTM") in London. 

2022-11-03 18:16 1958

First in-human use of OncoRes Medical's cancer imaging system successful

Quantitative Micro-Elastography (QME) Imaging System published in peer reviewed Cancer Research PERTH, Australia, Nov. 3, 2022 /PRNewswire/ -- OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled...

2022-11-03 06:00 1601

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today annou...

2022-11-02 21:00 2555

Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030

* Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong), the South Korea -based global healthcare company, announced the phase III clinical tri...

2022-11-02 09:00 1630

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...

2022-11-02 08:10 2007

SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation

- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...

2022-11-02 02:00 1770

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC

SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-lin...

2022-11-01 21:32 2949

Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference

SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial OfficerJosh House and Chief Deve...

2022-11-01 20:00 1289

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...

2022-11-01 19:40 1908

Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company

With more than 1,600 employees across the globe, the new organization is now one of the world's largest pharma intelligence solutions providers on the market YARDLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies...

2022-11-01 19:00 2982
1 ... 96979899100101102 ... 291